Mechanism of lipid‐lowering action of the dipeptidyl peptidase‐4 inhibitor, anagliptin, in low‐density lipoprotein receptor‐deficient mice

AIMS/INTRODUCTION: Dipeptidyl peptidase‐4 inhibitors are used for treatment of patients with type 2 diabetes. In addition to glycemic control, these agents showed beneficial effects on lipid metabolism in clinical trials. However, the mechanism underlying the lipid‐lowering effect of dipeptidyl pept...

Descripción completa

Detalles Bibliográficos
Autores principales: Yano, Wataru, Inoue, Noriyuki, Ito, Shiori, Itou, Takahiro, Yasumura, Misako, Yoshinaka, Yasunobu, Hagita, Sumihiko, Goto, Moritaka, Nakagawa, Takashi, Inoue, Keisuke, Tanabe, Sohei, Kaku, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334308/
https://www.ncbi.nlm.nih.gov/pubmed/27860391
http://dx.doi.org/10.1111/jdi.12593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334308/
https://www.ncbi.nlm.nih.gov/pubmed/27860391
http://dx.doi.org/10.1111/jdi.12593

Ejemplares similares